Cargando…

PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis

INTRODUCTION: Rheumatoid arthritis (RA) often involves an altered T-cell subpopulation, higher levels of inflammatory cytokines, and auto-antibodies. This study investigated whether PDCD5 could be a biomarker to predict the incidence and remission of RA so as to guide the therapeutic management of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Juan, Zhou, Fengqiao, Zhao, Zhenwang, Cao, Fengsheng, Xiao, Hong, Zhang, Lu, Chen, Huabo, Wang, Ke, Zhang, Anbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468452/
https://www.ncbi.nlm.nih.gov/pubmed/37528307
http://dx.doi.org/10.1007/s40744-023-00587-5
_version_ 1785099240371912704
author Xiao, Juan
Zhou, Fengqiao
Zhao, Zhenwang
Cao, Fengsheng
Xiao, Hong
Zhang, Lu
Chen, Huabo
Wang, Ke
Zhang, Anbing
author_facet Xiao, Juan
Zhou, Fengqiao
Zhao, Zhenwang
Cao, Fengsheng
Xiao, Hong
Zhang, Lu
Chen, Huabo
Wang, Ke
Zhang, Anbing
author_sort Xiao, Juan
collection PubMed
description INTRODUCTION: Rheumatoid arthritis (RA) often involves an altered T-cell subpopulation, higher levels of inflammatory cytokines, and auto-antibodies. This study investigated whether PDCD5 could be a biomarker to predict the incidence and remission of RA so as to guide the therapeutic management of clinical RA. METHODS: One hundred fifty-two patients (41 being in both active status and stable remission status) who were newly diagnosed with RA and 38 healthy controls were enrolled. Basic clinical data were collected before using blood samples remaining in the clinic after routine complete blood count. The ability of PDCD5 and important indicators to predict the remission of RA was estimated based on receiver operating characteristic curve (ROC) analysis. RESULTS: PDCD5 expression was found to be significantly increased in RA patients in active status in comparison with healthy controls or those in stable remission status. Compared with anti-CCP, ESR and DAS28 score, PDCD5 was of better predictive value with an AUC of 0.846 (95% CI 0.780–0.912) for RA remission. The incidence risk of RA increased with higher levels of PDCD5 (OR = 1.73, 95% CI = 1.45–1.98, P = 0.005) in multiple logistic regression analysis, with the risk increasing by 2.94-times for high-risk group in comparison with low-risk group (OR = 2.94, 95% CI = 2.35–4.62, P < 0.001). The association between PDCD5 and RA remission showed a similar result. For correlation analysis, significant associations were eventually found between PDCD5 and indicated genes (FOXP3, TNF-α, IL-17A, IFN-γ and IL-6) as well as several important clinical parameters including IgG, RF, CRP, ESR, anti-CCP and DAS28 score. CONCLUSIONS: This study suggested that increased PDCD5 expression was significantly linked to the incidence and remission of RA. PDCD5 may be used as a novel biomarker for the prediction of RA incidence and remission, especially due to its potential involvement in the development of the condition.
format Online
Article
Text
id pubmed-10468452
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-104684522023-09-01 PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis Xiao, Juan Zhou, Fengqiao Zhao, Zhenwang Cao, Fengsheng Xiao, Hong Zhang, Lu Chen, Huabo Wang, Ke Zhang, Anbing Rheumatol Ther Original Research INTRODUCTION: Rheumatoid arthritis (RA) often involves an altered T-cell subpopulation, higher levels of inflammatory cytokines, and auto-antibodies. This study investigated whether PDCD5 could be a biomarker to predict the incidence and remission of RA so as to guide the therapeutic management of clinical RA. METHODS: One hundred fifty-two patients (41 being in both active status and stable remission status) who were newly diagnosed with RA and 38 healthy controls were enrolled. Basic clinical data were collected before using blood samples remaining in the clinic after routine complete blood count. The ability of PDCD5 and important indicators to predict the remission of RA was estimated based on receiver operating characteristic curve (ROC) analysis. RESULTS: PDCD5 expression was found to be significantly increased in RA patients in active status in comparison with healthy controls or those in stable remission status. Compared with anti-CCP, ESR and DAS28 score, PDCD5 was of better predictive value with an AUC of 0.846 (95% CI 0.780–0.912) for RA remission. The incidence risk of RA increased with higher levels of PDCD5 (OR = 1.73, 95% CI = 1.45–1.98, P = 0.005) in multiple logistic regression analysis, with the risk increasing by 2.94-times for high-risk group in comparison with low-risk group (OR = 2.94, 95% CI = 2.35–4.62, P < 0.001). The association between PDCD5 and RA remission showed a similar result. For correlation analysis, significant associations were eventually found between PDCD5 and indicated genes (FOXP3, TNF-α, IL-17A, IFN-γ and IL-6) as well as several important clinical parameters including IgG, RF, CRP, ESR, anti-CCP and DAS28 score. CONCLUSIONS: This study suggested that increased PDCD5 expression was significantly linked to the incidence and remission of RA. PDCD5 may be used as a novel biomarker for the prediction of RA incidence and remission, especially due to its potential involvement in the development of the condition. Springer Healthcare 2023-08-01 /pmc/articles/PMC10468452/ /pubmed/37528307 http://dx.doi.org/10.1007/s40744-023-00587-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Xiao, Juan
Zhou, Fengqiao
Zhao, Zhenwang
Cao, Fengsheng
Xiao, Hong
Zhang, Lu
Chen, Huabo
Wang, Ke
Zhang, Anbing
PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis
title PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis
title_full PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis
title_fullStr PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis
title_full_unstemmed PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis
title_short PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis
title_sort pdcd5 as a potential biomarker for improved prediction of the incidence and remission for patients with rheumatoid arthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468452/
https://www.ncbi.nlm.nih.gov/pubmed/37528307
http://dx.doi.org/10.1007/s40744-023-00587-5
work_keys_str_mv AT xiaojuan pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT zhoufengqiao pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT zhaozhenwang pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT caofengsheng pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT xiaohong pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT zhanglu pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT chenhuabo pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT wangke pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis
AT zhanganbing pdcd5asapotentialbiomarkerforimprovedpredictionoftheincidenceandremissionforpatientswithrheumatoidarthritis